MassMutual Ventures has followed up on the $50m Southeast Asian fund it launched in late 2018 with a second vehicle dedicated to the region.
The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.
SymphonyAI Group has taken part in a $150m round for one of its spinoffs, precision cancer therapy developer Concerto HealthAI.
Naver has backed four health and education technology developers – Huray Positive, Ichrogene, N.Cer and SoundGym – through its D2 Startup Factory accelerator.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Takeda Ventures converted debt financing into equity through the genetic medicine developer's latest round, which was led by strategic partner AnGes.
University of Pittsburgh Medical Center’s investment and innovation arm has allocated $1bn to drug development funding over the next four years.
GV was among the investors as long-term care support provider CareBridge emerged from stealth with $40m and two acquisitions.